Humacyte Inc. (HUMA) has announced a strategic realignment of ex-U.S. rights for its bioengineered tissue product, Symvess, which is designed to repair blood vessels damaged by vascular trauma. This development follows the FDA’s approval of the biologics license application for the acellular tissue engineered vessel (ATEV) in December 2024. The agreement with Fresenius Medical Care grants Humacyte exclusive distribution rights outside the U.S., with a low single-digit royalty structure on net sales.
This move is significant as it expands Humacyte’s global reach and revenue potential, particularly in treating critical conditions associated with vascular trauma. The company is also progressing preclinical trials for ATEV in various applications, including coronary artery bypass and pediatric heart surgery, which could further enhance its market position.
Investors should note that HUMA’s current trading price of $0.71 reflects a modest increase, but the realignment and ongoing developments in clinical trials may impact future valuation and market sentiment.
Source: nasdaq.com